About
Titles
Staff Affiliate - Other
Appointments
Departments & Organizations
Education & Training
- MD
- New York Medical College (1979)
Research
Publications
2024
The journal of thrombosis and thrombolysis: commemorating the written word in science and medicine: three decades and counting
Becker R. The journal of thrombosis and thrombolysis: commemorating the written word in science and medicine: three decades and counting. Journal Of Thrombosis And Thrombolysis 2024, 1-6. PMID: 38980568, DOI: 10.1007/s11239-024-03012-y.Peer-Reviewed Original ResearchAssessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis
Harrington J, Hellkamp A, Mahaffey K, Breithardt G, Halperin J, Hankey G, Becker R, Nessel C, Berkowitz S, Fox K, Singer D, Goodman S, Patel M, Piccini J. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal Of The American Heart Association 2024, 13: e028951. PMID: 38780169, PMCID: PMC11255646, DOI: 10.1161/jaha.122.028951.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAtrial fibrillationROCKET AFClinical trialsEnd pointsLow overall event ratesInternational double-blindClinical trials of interventionsRandomized clinical trialsAssessment of dayOverall event rateDouble-blindAnticoagulation trialsTreatment armsIncreased riskWarfarinTrials of interventionsClinical utilityTreatment groupsEvent ratesPatientsDAOHPoisson regressionComorbiditiesFibrillationTrialsFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 1-14. PMID: 38622277, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trialsTemporal biomarker concentration patterns during the early course of acute coronary syndrome
Eggers K, Batra G, Lindahl B, Lakic T, Lindbäck J, Budaj A, Cornel J, Giannitsis E, Katus H, Storey R, Becker R, Siegbahn A, Wallentin L. Temporal biomarker concentration patterns during the early course of acute coronary syndrome. Clinical Chemistry And Laboratory Medicine 2024, 62: 1167-1176. PMID: 38341860, DOI: 10.1515/cclm-2023-1253.Peer-Reviewed Original ResearchAltmetricConceptsAcute coronary syndromeST-elevation myocardial infarctionSymptom onsetNSTE-ACSHs-cTnTGDF-15Concentrations of high-sensitivity cardiac troponin TNon-ST-elevation acute coronary syndromeHigh-sensitivity cardiac troponin TPro-B-type natriuretic peptideBiomarker patternsAcute coronary syndrome patientsGrowth differentiation factor 15Cardiac troponin TC-reactive proteinPathophysiological processesBiomarker concentrationsClinically useful informationPlatelet inhibitionNatriuretic peptideHs-cTnICoronary syndromeTroponin TEarly courseAssociated with time
2023
Evaluating chest pain in patients with post COVID conditions permission to think outside of the box
Becker R. Evaluating chest pain in patients with post COVID conditions permission to think outside of the box. Journal Of Thrombosis And Thrombolysis 2023, 55: 592-603. PMID: 37052772, PMCID: PMC10098243, DOI: 10.1007/s11239-023-02808-8.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.
Thomas M, James S, Becker R, Himmelmann A, Katus H, Cannon C, Steg P, Siegbahn A, Lakic T, Storey R, Wallentin L. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 2019 PMID: 33609104, DOI: 10.1177/2048872619878075.Peer-Reviewed Original ResearchConceptsWhite blood cell countBaseline inflammatory markersTicagrelor compared to clopidogrelBlood cell countInflammatory markersC-reactive proteinAcute coronary syndromePrimary endpointCardiovascular deathCell countNeutrophil countClinical outcomesAcute coronary syndrome treated with ticagrelorCoronary syndromeCardiovascular benefitsN-terminal pro-brain-type natriuretic peptideInterleukin-6Increased risk of adverse cardiovascular eventsQuartile of white blood cell countComposite of cardiovascular deathAssociated with clinical outcomesRisk of adverse cardiovascular eventsLevels of inflammatory markersAcute coronary syndrome patientsPLATO study
Clinical Care
Overview
Clinical Specialties
Radiology & Biomedical Imaging
Board Certifications
Neuroradiology
- Certification Organization
- AB of Radiology
- Latest Certification Date
- 2015
- Original Certification Date
- 1995
Diagnostic Radiology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 1984
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileGet In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.